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Abstract
Background: Teicoplanin is a glycopeptide antibiotic used clinically in Europe and in Japan for the treatment of
multi-resistant Gram-positive infections. It is produced by fermenting Actinoplanes teichomyceticus. The
pharmaceutically active principle is teicoplanin A2, a complex of compounds designated T-A2-1-A2-5 differing in the
length and branching of the fatty acid moiety linked to the glucosamine residue on the heptapeptide scaffold.
According to European and Japanese Pharmacopoeia, components of the drug must be reproduced in fixed
amounts to be authorized for clinical use.
Results: We report our studies on optimizing the fermentation process to produce teicoplanin A2 in A.
teichomyceticus ATCC 31121. Robustness of the process was assessed on scales from a miniaturized deep-well
microtiter system to flasks and 3-L bioreactor fermenters. The production of individual factors T-A2-1-A2-5 was
modulated by adding suitable precursors to the cultivation medium. Specific production of T-A2-1, characterized by
a linear C10:1 acyl moiety, is enhanced by adding methyl linoleate, trilinoleate, and crude oils such as corn and
cottonseed oils. Accumulation of T-A2-3, characterized by a linear C10:0 acyl chain, is stimulated by adding methyl
oleate, trioleate, and oils such as olive and lard oils. Percentages of T-A2-2, T-A2-4, and, T-A2-5 bearing the iso-C10:0,
anteiso-C11:0, and iso-C11:0 acyl moieties, respectively, are significantly increased by adding precursor amino acids
L-valine, L-isoleucine, and L-leucine. Along with the stimulatory effect on specific complex components, fatty acid
esters, oils, and amino acids (with the exception of L-valine) inhibit total antibiotic productivity overall. By adding
industrial oils to medium containing L-valine the total production is comparable, giving unusual complex
compositions.
Conclusions: Since the cost and the quality of teicoplanin production depend mainly on the fermentation process,
we developed a robust and scalable fermentation process by using an industrial medium in which a complex
composition can be modulated by the combined addition of suitable precursors. This work was performed in the
wild-type strain ATCC 31121, which has a clear genetic background. This is important for starting a rational
improvement program and also helps to better control teicoplanin production during process and strain
development.
Background
Glycopeptide antibiotics such as vancomycin and teico-
planin are frequently used to treat life-threatening infec-
tions caused by multi-drug-resistant Gram-positive
pathogens. They are linear heptaptides produced by
nonribosomal peptide synthetase, further oxidatively
linked among aromatic amino acids and decorated with
chlorine atoms, glycosidic moieties, and (in the case of
teicoplanin) lipid chains. Vancomycin, introduced into
clinical practice in 1958, is produced from the actinomy-
cete Amycolatopsis orientalis, whereas teicoplanin, used
in hospitals in Europe and Japan since 1988 and 1998,
respectively, is from Actinoplanes teichomyceticus [1-3].
Both compounds are known to inhibit the formation of
the bacterial cell wall by binding to the N-acyl-D-alanyl-
D-alanine terminal of lipid II, thereby terminating the
subsequent transpeptidation and transglycosylation reac-
tions in the late extracellular stages of peptidoglycan
biosynthesis. Lipoglycopeptides such as teicoplanin and
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vancomycin against methicillin-resistant Staphylococcus
aureus, as they carry an extra aliphatic acyl side chain
on glucosamine at residue 4 (Figure 1A). Such a modifi-
cation may enable lipoglycopeptides that are anchored
on the lipid layer of the bacterial membrane to be close
to cell wall precursors [1,2].
Although vancomycin and teicoplanin have been com-
pletely synthesized, the complexity of these natural pro-
ducts renders fermentation the only viable route for
producing them pharmaceutically. Teicoplanin is pro-
duced by fermenting A. teichomyceticus ATCC 31121, as
a complex of structurally related molecules differing in
the length and branching of the fatty acid moiety linked
to the glucosamine residue on the heptapeptide scaffold
[4]. The common core of teicoplanin (Figure 1A) con-
sists of seven aromatic amino acids, which, apart from
the tyrosine residue at position 2, are nonproteinogenic
amino acids: three p-hydroxyphenylglycine residues at
positions 1, 4, and 5; two dihdroxyphenylglycine at posi-
tions 3 and 7; and one b-hydroxytyrosine at position 6.
Three ether bonds link amino acids at positions 1-3, 2-
4, and 4-6, and one C-C link between amino acids 5-7
joins aryl groups. The tyrosine and the b-hydroxytyro-
sine residues at positions 2 and 6 contain a chlorine
atom. Three sugar moieties are attached to the aryl
Figure 1 Teicoplanin A2 (T-A2) chemical structure and Targocid complex.I nA, the chemical structure of teicoplanin core shows that the
different components T-A2-1, T-A2-2, T-A2-3, T-A2-4, and T-A 2-5 vary in the acyl chain linked to the glucosamine residue on the heptapeptide
scaffold. In B, a pure sample of teicoplanin (Targocid, Sanofi-Aventis) was analyzed by the HPLC method described in the Methods. In these
conditions, T-A2-1, T-A2-2, T-A2-3, T-A2-4, and T-A 2-5 represent 6, 58.3, 7.3, 14.4, and 14% of the total T-A2.
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D-glucosamine at amino acid 6, and a N-fatty acyl-b-D-
glucosamine at position 4. Enzymes involved in synthe-
sizing the precursor aromatic nonproteinogenic amino
acids, assembling them in the heptapetide precursor,
and cross-linking, halogenating, and adding sugars to
them are encoded by genes clustered on the A. teicho-
myceticus chromosome [5,6]. The acyl chains linked to
glucosamine at position 4 are linear or branched nine-,
ten-, eleven-, twelve-carbon acids thought to be derived
from ß-oxidation of longer fatty acids contained in the
membrane pool of A. teichomyceticus [7].
The pharmaceutically active principle produced by
fermentation is teicoplanin A2 (T-A2), a complex of
five related compounds designated teicoplanin A2-1-A2-
5, characterized by five different linear or branched
ten- or eleven-carbon fatty acids (Figure 1A), which
accounts for 89 to 95% of the total teicoplanin com-
plex. A sixth, more polar active component, teicopla-
nin A3, which is not found in fermentation broth, is
always present in crude or purified extracts; it is a
hydrolytic product of T-A2 [8]. Especially according to
the European Pharmacopoeia, which is much more
restrictive than the Japanese guidelines [9], the six sub-
components should be present in the active pharma-
ceutical ingredient in rigorously fixed proportions.
Although it is unlikely that small variations in the
composition of active fractions significantly affect the
biological activity and/or safety and efficacy of the
drug in vivo, nowadays the responsible authorities do
not permit the Pharmacopoeia specifications of com-
plex composition to be different from the one regis-
tered for the innovator drug Targocid (Figure 1B).
Since the cost and the quality of teicoplanin depend
mainly on the fermentation process, we investigated
whether Actinoplanes teichomyceticus ATCC 31121
could be used as a cell factory for producing the drug.
Particular attention was given to modulating the com-
plex composition by adding fatty acid precursors or
their amino acid precursors to the fermentation process,
due to the importance for the aforementioned manufac-
turing guidelines.
Results
Single-factor optimization of teicoplanin production
medium
Four complex industrial media previously described in
the original patent and in the more recent literature on
producing teicoplanin by Actinoplanes teichomyceticus
were used to assay T-A2 production in the ATCC 31121
strain: E1 [10], TE/20 [7], Medium 1 [11], and Medium
2 [12] were selected since they differ mainly in carbon
and nitrogen sources and salt content. Briefly, A. teicho-
myceticus grew well in these media (protocols to prepare
reproducible cultures are described in the Methods) but
produced only from 0 to 25 mg/L T-A2. The highest
productivity was obtained in TE/20 (containing glucose
at 20 g/L and maltose at 20 g/L as carbon sources, cot-
tonseed meal at 15 g/L, and yeast extract at 6 g/L as
nitrogen sources, and CaCO3 at 6 g/L as the only added
salt), which was then selected as our starting point for
further optimization by quantitatively/qualitatively chan-
ging its components in single-factor experiments.
Various carbon sources, including glycerol, D-manni-
tol, D-mannose, D-glucose, sucrose, malt extract, dex-
trin, and soluble starch (all at the concentration of 20 g/
L), were tested in TE/20 with regard to the growth of A.
teichomyceticus (measured as Packed Mycelium Volume,
PMV) and the production of T-A2, respectively. The
results (Figure 2A) revealed that all these sugars sus-
tained biomass production to different extents, but malt
extract, an industrial component often used by the fer-
mentation industry, was the most effective carbon
source to support T-A2 production, which subsequently
improved to 70 mg/L. Inorganic nitrogen sources (15 g/
L) such as ammonium sulfate, simple organic sources
such as urea, and protein complex hydrolysates such as
meat extract, hydrolysate of casein, tryptone, soy pep-
tone, yeast extract, and soybean meal were tested next,
replacing cottonseed meal in TE/20, respectively. Figure
2B shows that soybean meal was the best nitrogen
source for sustaining biomass production, whereas yeast
extract was the best candidate for producing T-A2. Two
industrially used derivatives from cottonseed meal, Phar-
maflo and Pharmamedia (Pharmamedia Archer Daniels
Midland Company, IL, USA), were also tested as possi-
ble alternatives to soybean meal, but they did not show
significant improvement either in biomass or T-A2 pro-
duction (data not shown) and were thus abandoned.
In a following set of experiments (not shown), differ-
ent concentrations of glucose (10, 20, 30 g/L) and malt
extract (10, 20, 30 g/L) as carbon sources and soybean
meal (5, 15, 20 g/L) and yeast extract (5, 15, 20 g/L) as
nitrogen sources were combined and antibiotic produc-
tion evaluated. The optimal concentration of malt
extract was found to be 30 g/L in the presence of 10 g/
L glucose, and a combination of soybean meal at 15 g/L
and yeast extract at 5 g/L supported higher titers of T-
A2. Under these conditions, 100 mg/L (s = ± 14, 6 mg/
L) T-A2 was produced at flask fermentation scale (Fig-
ure 3A). Finally, different concentrations of CaCO3,
which was the only salt added to the initial TE/20 med-
ium, were also tested. By removing CaCO3 or adding it
at 2 g/L, T-A2 production was reduced by 70 and 40%,
respectively. No changes in T-A2 production were
achieved by adding 4 or 6 g/L CaCO3.T h u s ,t h en o v e l
T-A2 production medium was determined to consist of
30 g/L malt extract, 10 g/L glucose, 15 g/L soybean
Taurino et al. Microbial Cell Factories 2011, 10:82
http://www.microbialcellfactories.com/content/10/1/82
Page 3 of 13meal, 5 g/L yeast extract, and 4 g/L CaCO3.T h i sc o m -
plex industrial medium was termed Teicoplanin Med-
ium 1 (TM1).
In TM1 flask fermentation, onset of growth was observed
after a lag phase of about 20 hours, which coincided with a
slight increase in medium pH. A rapid decrease in free glu-
cose concentration preceded the start of T-A2 production,
which ensued at ca. 48 hours after inoculation and reached
its maximum at 120-144 hours (Figure 3A). Under these
conditions, the T-A2 complex showed the subcomponent
composition reported in Figure 3B.
Fermentation from a miniaturized system to bioreactor
scale
A. teichomyceticus growth and T-A2 production were
tested in commercially available, square, deep-well poly-
propylene microtiter plates (24-SDW MTPs) with sand-
wich covers (System Duetz [13]), consisting of 24 wells
filled with 2.5 mL production medium each. We
thought that deep-well plates could considerably reduce
the work load and cost of the investigation while
Figure 2 Optimization of teicoplanin production medium. Effect
of different carbon (A) and nitrogen (B) sources on growth (PMV,
empty bars) and T-A2 production (mg/L, filled bars) by A.
teichomyceticus ATCC 31121. Carbon sources were tested at 20 g/L
replacing maltose in TE/20. Nitrogen sources were tested at 15 g/L
replacing cottonseed meal in TE/20.
Figure 3 Fermentation of A. teichomyceticus ATCC 31121 at
flask scale in TM1 medium.I n( A), time courses of pH (□, dashed
line), glucose (▲, dashed line), growth curve measured as PMV (○,
solid line), and T-A2 production (●, solid line). In (B), HPLC profile of
144-hour sample showing the following complex composition: T-A2-
1, T-A2-2, T-A2-3, T-A2-4, and T-A 2-5 represent 7.3, 60.2, 13.1, 9.1, and
10.3% of the total T-A2.
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growing filamentous microorganisms to produce anti-
biotics in industrially and not completely soluble rich
media, the use of such miniaturized systems is often
limited by insufficient aeration and poor mixing [13-15].
As described in the Additional file 1, the dissolved
oxygen (DO) concentration is a crucial parameter in T-
A2 production by A. teichomyceticus. The teicoplanin
dependence on DO was indirectly demonstrated by
increasing the volume of production medium (thus
reducing the oxygen transfer rate) in 300 ml Erlenmeyer
flaks: T-A2 titer decreased when 300 ml Erlenmeyer
flasks were filled with increasing working volumes of
TM1 (Additional file 1, Figure S1). The direct effect of
DO (measured as % pO2) on T-A2 production was mon-
itored at the bench reactor scale: comparison of Figure
S2 (Additional file 1) and Figure 4 (see below)
demonstrates the positive effect of controlling pO2 by
varying the agitation speed. In uncontrolled, 3-L fermen-
tations runs, where pO2 rapidly tended to zero in 25
hours, 25-30% less T-A2 was produced (Figure S2, Addi-
tional file 1) in comparison to those runs in which pO2
was maintained above 20% of saturation (Figure 4).
Notwithstanding this dependence on oxygen rate, T-A2
production was well reproducible in 24-SDW MTPs: the
average productivity in the 24 wells at 120-144 hours
was 100 mg/L (s = ± 10 mg/L), which compared favor-
ably with data obtained in flasks. The HPLC profile of
T-A2 complex composition in 24-SDW MTPs over-
lapped with the one shown in Figure 3B. This good per-
formance of the miniaturized System Duetz is likely due
to the favorable volume (2.5 mL working volume in 12.5
mL total well volume), geometry (square-instead of clas-
sical round-bottom wells), and special covers, which
allowed agitation on a rotatory shaker and avoided eva-
poration and cross-contamination [13-15].
The robustness of the teicoplanin fermentation pro-
cess was also confirmed by scaling it up to fermenters.
Figure 4 shows a typical time course of A. teichomyceti-
cus fermentation in TM1 at a 3-L fermenter scale,
where pO2 was maintained over 20% of saturation (see
also Figure S2, Additional file 1). Growth curve moni-
tored by dry weight indicate that A. teichomyceticus
exponentially grew up to 48 hours after inoculation,
then growth rate tended to diminished, and after 120
hours from the inoculation a secondary exponential
growth phase is observed as previously shown by other
authors [16]. Glucose consumption was completed in
the first 48 hours and preceded T-A2 production, which
reached its maximum at 96-120 hours after inoculation
(volumetric productivity of 234 mg/L of culture with s
= ± 16 mg/L, specific productivity of 1.3 mg/g of bio-
mass). pH tended to increase slowly after the first 24
hours of fermentation from 6, reaching 8 during the last
phase of the process. Fermentations run by controlling
pH at 7 by adding acid after 24-48 hours of growth did
not improve T-A2 production (Figure S3, Additional file
1 )a n dt h u sw ed i dn o ti n t r o d u c ep Hc o n t r o li no u r
reference fermentations. The HPLC profile of T-A2
composition at 120 hours of fermentation described in
Figure 4 overlaps with that shown in Figure 3B.
Modulation of teicoplanin complex composition
The production of individual T-A2 factors was modu-
lated by adding suitable precursors to the industrial pro-
duction medium TM1. Factors T-A2-1 and T-A2-3 are
characterized by linear 4-n-decenoic (n-C10:1) and n-
decanoic (n-C10:0) fatty acids, respectively, linked by an
amide bond to the glucosamine residue (Figure 1). Pre-
vious data [7,17] showed that 4-n-decenoic and n-
decanoic fatty acids in teicoplanin derive from b-
Figure 4 Growth and teicoplanin production in 3-L batch
fermentations of A. teichomyceticus ATCC 31121 in TM1. The
pH value was naturally self-regulated (i.e., it was not controlled by
adding acid/base during the fermentation), whereas the pO2 was
controlled over the 20% of saturation by adjusting agitation speed.
In (A), time courses of pH (●, solid line), pO2 (□, dashed line),
glucose (▲, solid line), and growth curve measured as dry weight (Δ,
dashed line) and PMV (■, solid line). In (B), production of T-A2
measured by HPLC analysis as mg/L (filled bars).
Taurino et al. Microbial Cell Factories 2011, 10:82
http://www.microbialcellfactories.com/content/10/1/82
Page 5 of 13oxidation of linoleic (n-C18:2) and oleic (n-C18:1) acids,
respectively. We investigated the effect of adding these
C-18 fatty acids as free acids, methyl esters, and trigly-
cerides to TM1 on T-A2 production and finally of sup-
plying them as main components in raw materials such
as available crude oils. Adding free acids was ruled out
immediately due to their toxicity even at low concentra-
tions (0.5 g/L), which blocked A. teichomyceticus
growth. Different concentrations of methyl esters of
oleic acid and linoleic acids were added to the fermenta-
tion medium at the time of inoculation. As shown in
Table 1, adding methyl linoleate or trilinoleate stimu-
lated the production of T-A2-1 factor, which reached 20-
30% of the total T-A2 complex, whereas methyl oleate
and trioleate increased the relative T-A2-3 productivity
to 30-50%. Indeed, a common feature of adding these
esters was the dose-dependent reduction in T-A2 com-
plex production as a whole. A concentration of methyl
linoleate higher than 2 g/L abolished T-A2 production.
Adding increasing concentrations of crude oils with
different percentage compositions in linoleic and oleic
acids (see Table 2) confirmed the dose-effect response
in stimulating the synthesis of T-A2-1 and T-A2-3 fac-
tors, respectively, and in reducing total T-A2 production.
Adding oils rich in linoleic acid (i.e., safflower, corn, and
cottonseed oils) increased T-A2-1 relative productivity
up to 30-60% of the total complex, whereas oils rich in
oleic acid (i.e., olive, almond, canola, and lard oils)
enhanced T-A2-3 nearly to 30-50% (see representative
HPLC profiles in Additional file 2, Figures S4A and
S4B). Oils that contain similar amounts of linoleic and
oleic acids (i.e., sesame and soybean oils) gave an unu-
sual complex containing comparable amounts of T-A2-1
and T-A2-3 factors (see HPLC profile in Figure S4C,
Additional file 2). The only exception to the common
inhibitory action that these additions to T-A2 complex
production afforded was safflower oil; safflower oil
increased the total T-A2 titer slightly, but gave a com-
plex composition enriched in T-A2-1 and T-A2-3 factors,
which turned out to be quite different from the control
(Table 2).
Factors T-A2-2,T - A 2-4,a n dT - A 2-5 are characterized
by branched fatty acids: 8-methylnonanoic (iso-C10:0),
8-methyldecanoic (anteiso-C11:0), and 9-methyldecanoic
(iso-C11:0) acid, respectively (Figure 1). Their precursors
were identified as the cell membrane fatty acids 14-
methyl pentadecanoic (iso-C16:0), 14-methylesadecanoic
(anteiso-C17:0), and 13-methyltetradecanoic (iso-15:0)
acid, whose biosynthesis was significantly enhanced by
adding amino acids L-valine, L-isoleucine, and L-leucine
to the medium [7,18-20]. Isobutyrate, isovalerate, and 2
methylbutyrate represent the starting molecules for
synthesizing even-carbon iso acids, odd-carbon iso acids,
and odd-carbon anteiso acids, but they could not be
directly added to A. teichomyceticus cultures owing to
their toxicity; thus they were indirectly supplied by add-
ing the precursor amino acids, as shown in Table 1. L-
valine increased the production of T-A2-2 to 70-80% of
the T-A2 complex, whereas L-isoleucine or L-leucine
increased the relative yields of T-A2-4 to more than 30%
or T-A2-5 to more than 20%, respectively. Increasing
concentrations of L-leucine and L-isoleucine progres-
sively inhibited T-A2 complex composition, whereas the
addition of L-valine caused a marked improvement (60-
90% more) in total T-A2 productivity.
The positive effect of L-valine on total T-A2 produc-
tivity was combined with the addition of corn oil and
olive oil, which, when used alone, stimulated T-A2-1 and
T-A2-3 production but reduced total antibiotic
Table 1 Effect of biosynthesis precursors on teicoplanin
production.
Percentage composition
Addition Total T-A2 T-A2-1 T-A2-2 T-A2-3 T-A2-4 T-A2-5
None 100 7.3 60.2 13.1 9.1 10.3
Methyl linoleate
0.5 g/L 31 3.2 49.7 16.9 17.1 13.1
1 g/L 28 10.6 49.3 17.0 13.0 10.1
2 g/L 17 29.0 31.0 18.8 10.0 11.2
4 g / L 0 00000
6 g / L 0 00000
Trilinoleate
2 g/L 21 21.9 43.1 15.1 10.1 9.8
Methyl oleate
0.5 g/L 38 2.8 56.2 16.3 13.1 11.6
1 g/L 17 2.2 46.2 20.3 19.3 12.0
2 g/L 12 4.0 40.2 25.7 14.9 15.2
4 g/L 10 7.0 31.6 30.7 16.7 14.0
6 g/L 9 5.8 29.9 31.1 17.7 15.5
Trioleate
2 g/L 75 7.6 31.8 49.7 6.1 4.9
L-valine
1 g/L 160 6.2 77 12.9 1, 9. 2
2 g/L 191 6.1 80 11.9 1 1
3 g/L 148 6.3 74 14.2 3 2, 5
L-isoleucine
1 g/L 65 10 42 13 28 7
2 g/L 50 11.1 39.1 12.6 30 7.2
3 g/L 32 10 34.3 14 35.5 6, 2
L-leucine
1 g/L 85 7 50 13 10 23
2 g/L 70 9 49 15 2 25
3 g/L 60 8.1 48 16.6 3.9 23.4
A. teichomyceticus ATCC 31121 was grown in TM1 medium added at the time
of inoculum with different biosynthetic precursors. Samples were harvested at
144 hours and analyzed by HPLC as reported in the Methods. Total T-A2
complex production in control condition (without additions) was set as 100%.
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Percentage composition
Addition Total T-A2 T-A2-1 T-A2-2 T-A2-3 T-A2-4 T-A2-5
None 100 7.3 60.2 13.1 9.1 10.3
Safflower oil
(80% L. - 11% O.)
2.5 g/L 106 29.0 35.3 21.0 4.7 10
5 g/L 126 20.5 41.7 22.1 5.1 10.6
10 g/L 98 24.8 37 22.3 5.3 10.6
Corn oil
(60% L. - 25% O.)
2.5 g/L 111 35.9 23.4 34.0 3.5 3.1
5 g/L 89 40.7 20.4 33.9 2.8 2.2
10 g/L 27 52.9 14.1 26.3 2.5 4.2
Cottonseed oil
(58% L. - 14% O.)
2.5 g/L 90 45.0 24.8 25.7 2.3 2.2
5 g/L 38 54.2 18.7 22.1 3.4 1.6
10 g/L 19 61.4 12.7 13.8 5.2 6.9
Soybean oil
(54% L. - 24% O.)
2.5 g/L 91 24.6 34.6 31.4 4.8 4.6
5 g/L 94 38.2 22.0 33 4.0 2.8
10 g/L 33 45.7 16.1 25.9 4.5 7.8
Sesame oil
(38% L. - 53% O.)
2.5 g/L 66 21.3 29.7 38.9 5.2 4.9
5 g/L 53 32 19.1 40.2 5.8 2.9
10 g/L 27 38.2 13.7 41 5.2 1.9
Olive oil
(8% L. - 78% O.)
2.5 g/L 57 7.2 44.3 34.1 8.3 6.1
5 g/L 49 5.6 46.4 33.7 8.3 6.0
10 g/L 21 8.5 26.9 47.1 13.9 3.6
Almond oil
(20% L. - 75% O.)
2.5 g/L 48 12.7 44.6 31.1 6.2 5.4
5 g/L 46 11.8 43.1 30.4 8.2 6.5
10 g/L 19 15.4 29.3 37.3 13.5 4.5
Canola oil
(23% L. - 60% O.)
2.5 g/L 47 9.7 48.9 26.8 8.3 6.3
5 g/L 47 13.8 41.3 34.1 6.2 4.6
10 g/L 23 16.2 27.6 38.7 13.5 4.0
Lard oil
(10% L. - 46% O.)
2.5 g/L 55 8.5 53.8 21.1 9.5 7.1
5 g/L 30 12.5 39.8 28.8 14.0 4.9
10 g/L 35 16 28.1 42.5 9.7 3.7
A. teichomyceticus ATCC 31121 was grown in TM1 medium added at the time of inoculation with different oils. Sample were harvested at 144 hours and
analyzed by HPLC as reported in the Methods. Total T-A2 complex production in control condition (without additions) was set as 100%. Oil composition in
linoleate (L.) and oleate (O.) percentages was reported from [29].
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addition of 2.5 g/L of oils and of 1 g/L of L-valine
restored T-A2 productivity to the control level, counter-
acting the inhibitory effect of adding oil alone. These
results indicate that complex composition can be modu-
lated by maintaining the specific effects exerted by bio-
synthetic precursors, without affecting total antibiotic
productivity. Figures S5 and S6 in the Additiona file 2
show the HPLC profiles representing the combined effect
of L-valine and selected oils on complex composition.
Optimized process at fermenter scale
The positive effect of adding L-valine to the industrial
medium TM1 was confirmed in 3-L fermenters, run as
reported above (pO2 maintained over the 20% of satura-
tion). As can be seen by comparing Figure 6 with Figure
4, adding amino acid slightly reduced biomass produc-
tion and prolonged the lag phase (as demonstrated by
the reduction in glucose consumption in the first 24
hours). Exponential growth was actually completed in
48 hours and maximum antibiotic productivity was
achieved at 96-120 hours. An increase in volumetric
(340 mg/L with s =±5m g / L )a n ds p e c i f i c( 2m g / go f
biomass) productivities of T-A2 consititutes the major
effect of adding L-valine. As expected, the HPLC profile
for T-A2 complex composition at 120 hours showed a
prevalence of T-A2-2, which comprised more than 70%
of the complex (Figure 7).
Discussion
Most of the papers published on teicoplanin production
in the last decade [4,11,12,16,21,22] report on efforts to
Figure 5 Production of teicoplanin in TM1 to which L-valine
and crude oils were added. Fermentation of A. teichomyceticus
ATCC 31121 was run in TM1 to which 2.5 g/L corn oil (A) or 2.5 g/L
olive oil was added (B) and different concentrations of L-valine. T-A2
production in control conditions (without oil and L-valine addition)
was set as 100%.
Figure 6 Growth and teicoplanin production in 3-L batch
fermentations of A. teichomyceticus ATCC 31121 in TM1 to
which L-valine was added. L-valine (2 g/L) was added at the time
of inoculation. The pH value was naturally self-regulated, whereas
the pO2 was controlled over the 20% of saturation by adjusting
agitation speed. In (A), time courses time course of pH (●, solid
line), pO2 (□, dashed line), glucose (▲, solid line), growth curve
measured as dry weight (Δ, dashed line), and PMV (■, solid line). In
(B), production of T-A2 measured by HPLC analysis as mg/L (filled
bars).
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which are produced by applying the classical approach
of random mutagenesis and selecting higher producer
strains. Classical strain improvement (CSI) still repre-
sents the most successful means of meeting the indus-
trial need for a rapid increase in the production yield of
antibiotic-producing microbes. Indeed, it generates
mutants with randomly uncontrolled, modified genome
backgrounds [23]. We recently initiated a program for
improving the A. teichomyceticus strain based on
rational metabolic engineering and recombinant DNA
technology, which may provide a novel, alternative strat-
egy for improving titers and that complements the
empirical method used in industry. For this purpose we
needed to establish a robust and reproducible process
with the wild-type strain at different fermentation scales.
Firstly, we developed a complex industrial medium
TM1 by single-factor experiments based on the compo-
sition of TE/20 medium published in the 1990’s[ 7 ] ;
here, we changed the quality and quantity of the essen-
tial components such as carbon sources, nitrogen
sources, and CaCO3. In this complex medium, inorganic
phosphate, which is known to inhibit the synthesis of
teicoplanin [16] and other teicoplanin-like glycopeptides
[24,25] when added to defined mineral media, is slowly
released during soybean meal and yeast extract con-
sumption, and its effect has not been further investi-
gated. Since two atoms of chlorine are present in the
teicoplanin molecule, we tested the effect of adding dif-
ferent concentrations of NaCl; however, no improve-
ment was observed, suggesting the chlorine content of
fermentation medium was already sufficient for produ-
cing T-A2. Exploiting TM1 medium, the optimal T-A2
titer was found to be around 100 mg/L, which is more
than five- to ten-fold better than in the initially screened
media. An important parameter to be assessed in teico-
planin production – for the reasons stated in the back-
ground section – is its complex composition, whose
factors differ by the length and branching of the fatty
acids chains. We were aware that nitrogen sources, and
to a lesser extent carbon sources, such as the ones used
in the TM1 formulation, contain variable compositions
of amino acids and fatty acids. These constituents can
supply a pool of precursors for diverse components of
the T-A2 complex, changing its relative composition in
comparison to the ones achieved in other media [7,17].
Secondly, total T-A2 production and complex compo-
sition in TM1 were found to be reproducible in the
miniaturized fermentation system previously described
by Duetz [13]. Thus, we were able to handle 24 mini-
fermentations in parallel, significantly reducing the
workload and the demand for shakers, flasks, media,
and analytical equipment during fermentation and strain
improvement programs. Previous investigations employ-
ing this miniaturized system mostly focused on bacteria
with unicellular dispersion and on determining growth
and primary metabolism. Only few studies have been
published on secondary metabolite production in fila-
mentous streptomycetes, i.e., actinorhodin [15] and
novobiocin [14]. To our knowledge, this is the first
report on antibiotic production in such a miniaturized
system by an Actinoplanes species, which belong to the
so-called rare genera of filamentous actinomycetes [26].
Reproducible total T-A2 production and complex
composition were also achieved when fermentation was
scaled up to laboratory fermenters, where indeed an
increase of up to more than 200 mg/L was obtained
when DO was kept over 20%. These data confirmed pre-
vious observations from a patented high producer
mutant at pilot (300 L) and plant (50, 000 L) scales,
where it was demonstrated that teicoplanin production
decreased significantly as DO was maintained below
20%, indicating that this parameter represents a major
concern in scaling up the process [4].
Numerous experts believe that, in a clinical setting,
teicoplanin should be treated as an entity, regardless of
the relative levels of subcomponents, since their relative
amounts, lipophilicity, and MICs do not predict signifi-
cant differences in pharmacokinetic characteristics.
Nevertheless, due to the Pharmacopoeia’s specifications
with respect to the individual glycopeptide subcompo-
nents (as mentioned in the Background), tools to
Figure 7 Teicoplanin profile in TM1 to which L-valine was
added. HPLC profile of sample harvested at 120 hours from the
fermentation of A. teichomyceticus ATCC 31121 in TM1 to which 2
g/L-valine was added. T-A2-1, T-A2-2, T-A2-3, T-A2-4, and T-A2-5
represent 7.3, 73.4, 10.5, 2.0, and 6.8% of the total T-A2.
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Page 9 of 13modulate teicoplanin complexes during manufacturing
might be very useful.
To this end, we applied a biosynthetic approach to
modulate T-A2, which was based on previous investiga-
tions of the origin of linear and branched-chain fatty
acids constituting the acyl moieties in T-A2 [7], in its
structurally closely related A40926 lipoglycopeptide
[18,20,27], and in the lipopeptide antibiotic ramoplanin
[19]. In these antibiotics acyl moieties derive from fatty
acid constituents of membrane lipids or from those exo-
genously added to the growth medium [7,17,20,27]. It
was observed that changes in fatty acid composition of
cell membranes in the producer actinomycetes caused
by feeding precursor amino acids corresponded well to
the fatty acid distribution within the produced teicopla-
nin, A40926, and ramoplanin complexes [7,18-20,27].
Previous studies [18,20] showed that when a single-
branched amino acid was added to a minimal medium
in Nonomuraea sp., which produce the teicoplanin-like
A40926, the biosynthesis of membrane fatty acids was
influenced not only by the products of the initial steps
of its catabolism, but also by the end products of the
pathway, depending on the affinity of the starters for the
fatty acid synthase. Nonomuraea sp.’s fatty acid synthe-
tase preferred isobutyric acid, which is provided by the
partial catabolism of L-valine present in the culture
medium, whereas isovaleryl-CoA generated from L-leu-
cine was only accepted as a substrate to a lesser extent,
and 2-methylbutyryl-CoA from L-isoleucine was not
recognized as a promoter. As a consequence of adding
L-isoleucine, its complete catabolism provided propionic
acid, which was extensively used by the fatty acid
synthetase as primer of fatty acids with an odd number
of carbons.
A similar interplay between the availability of the bio-
synthetic starters and the affinity of the starters for the
synthase could affect the changes in the membrane
composition of A. teichomyceticus and consequently the
composition of the teicoplanin that is produced. As in
the case of A40926 production in Nonomuraea sp., L-
valine addition improved teicoplanin-specific productiv-
ity, suggesting that biosynthesis of the corresponding
fatty acid represents a limiting step, which can be over-
come by adding the appropriate precursor. The fact that
other precursor amino acids and oils stimulated relative
production of the corresponding complex components,
but inhibited total antibiotic production likely reflects
the extent of the membrane perturbation caused by add-
ing massive amounts. In fact, in the cases of both Nono-
muraea sp. and A. teichomyceticus,t h em a j o r
component among the membrane fatty acids, in the
absence of added precursors, is the 14-methyl pentade-
canoic (iso-C16:0) fatty acid, which originates from L-
valine [7,19,20,27]. According to our hypothesis, the
increase upon adding L-valine causes a less perturbing
effect on membrane composition than adding L-leucine
and L-isoleucine, which substantially increases minor
fatty acid membrane components, or oils containing
long chain fatty acids that can alter membrane proper-
ties [19]. Restoration of control productivity in the case
of combined addition of L-valine and crude oils indir-
ectly confirms the need to maintain a membrane-equili-
brated composition.
These findings should stimulate further work to opti-
mize times for adding L-valine and crude oils to the fer-
mentation process of A. teichomyceticus,i no r d e rt o
obtain unusual complex compositions without affecting
membrane stability in the early phase of growth. Preli-
minary data show that the inhibitory effect of crude oils
on total teicoplanin production is lower if they are
added when the growth rate tends to be decreasing and
the cells are entering into the stationary phase of
growth. Taking into account the good performance
achieved at the fermenter level in TM1 to which L-
valine was added (T-A2 volumetric productivity more
than 300 mg/L), further experiments will be run in oil-
fed batch fermentations.
Conclusions
Most of the cost and quality of teicoplanin depends on
fermentation conditions, which typically change when
scaling up to an industrial process using valuable high
producer strains. We have developed a robust fermenta-
tion process by using an industrial medium, which can
be scaled down and up and in which complex composi-
tion can be modulated by the combined addition of sui-
table precursors such as amino acids and crude oils.
This work was carried out in the wild-type strain ATCC
31121, which has a clear genetic background. This is
important for starting a rational improvement program
and also helps to better control teicoplanin production
during process and strain development.
Methods
Microrganism
A. teichomyceticus ATCC 31121 was maintained as a
frozen vegetative stock at -80°C in 15% v/v glycerol at a
biomass concentration of approximately 0.08 g/mL DW
(dry weight). This working cell bank (WCB) was pre-
pared by streaking lyophilized mycelium on slants of
SM agar medium [28]. After growth, the mycelium from
the slant was homogenized in 10 mL of physiological
solution (0.9% w/v NaCl) and inoculated into 50 mL
liquid E25 [18] in a 300-mL baffled Erlenmeyer flask.
Flasks were incubated for 72 hours at 28°C and 220
rpm. Mycelium was collected by centrifugation, washed
by water, weighted, resuspended in 15% v/v glycerol and
stored as a WCB in 1.5 mL cryo-vials at -80°C.
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To start the fermentation process, one vial of the WCB
was inoculated into 300-mL baffled flasks containing 50
mL of vegetative medium E25. Flask cultures were incu-
bated for 72 hours on a rotary shaker at 220 rpm and
28°C and then used to inoculate (5% v/v): (i) 24-Square
Deep Well polypropylene microtiter plates (24-SDW
MTPs) purchased from EnzyScreen BV (Biopartner cen-
ter, Leiden, The Netherlands) containing 2.5 mL pro-
duction medium; (ii) 300-mL baffled Erlenmeyer flasks
containing 50 mL production medium, or (iii) 3 L P-100
Applikon glass reactor (height 25 cm, diameter 13 cm)
equipped with a AD1030 Biocontroller and AD1032
motor, containing 2 L production medium. Microtiter
plates and flasks were incubated at 28°C and 220 rpm
for 144-168 hours. Cultivations in fermenters were car-
ried out for 144-168 hours at 30°C, with stirring at 500-
900 rpm (corresponding to 1.17-2.10 m/s of tip speed)
and 2 L/min aeration rate. Dissolved oxygen (measured
as % pO2) was monitored using an Ingold polarographic
oxygen electrode and controlled by setting agitation
speed in cascade with a set point of 20% of saturation
with pO2. The pH values of culture broths were moni-
tored using a pH meter and controlled by adding H2SO4
(2, 5% v/v). Foam production was controlled by adding
Hodag antifoam through an antifoam sensor. Fermenta-
tion runs were replicated at least three times for each
experimental condition. Data were calculated as mean
values from three replicated fermentations.
Production media
E1 [10], TE/20 [7], Medium 1 [11], and Medium 2 [12]
were tested as production medium. Components of TE/
20 medium (carbon sources, nitrogen sources, and
CaCO3) were examined individually to determine their
contribution toward the production of T-A2 in A. tei-
chomyceticus ATCC 31121 (single-factor experiments).
Different concentrations of L-valine, L-isoleucine, L-
leucine, methyl linoleate, methyl oleate, trilinoleate,
trioleate, almond oil, canola oil, corn oil, cottonseed oil,
lard oil, safflower oil, sesame oil, and soybean oil, pre-
viously sterilized in an autoclave were added at the time
of inoculation to determine their effect on teicoplanin
production. All the amino acids and the oils used were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Analyses
Fermentation broth samples were collected at regular
time intervals and analyzed. Teicoplanin was extracted
by mixing 1 volume of whole culture and 1 volume of
borate buffer (100 mM H3BO3 (Sigma-Aldrich), 100
mM NaOH (Sigma-Aldrich), pH 12). Mixtures were
then centrifuged (16, 000 xgfor 15 min). The superna-
tant was collected and filtered through a Durapore
membrane filter (0.45 μm) (Millipore, Billerica, MA,
USA).
The glycopeptide production was estimated by HPLC
performed on a 5-μm particle size Symmetry C18 (VWR
International LCC, Radnor, PA, USA) column (4.6 × 250
mm) eluted at 1 mL/min flow rate with a 30-minute lin-
ear gradient from 15% to 65% of Phase B, followed by
10 minutes with 100% Phase B. Phase A was 32 mM
HCOONH4 (Sigma-Aldrich) pH 4.5:CH3CN (Sigma-
Aldrich) 90:10 (v/v) and Phase B was 32 mM
HCOONH4 pH 4.5:CH3CN 30:70 (v/v) mixture. The
chromatography was performed with a model 1100
HPLC system (Elite Lachrom VWR Hitachi LLC) and
UV detection was at 236 nm. As internal standard, pure
samples of teicoplanin (Targocid, Sanofi-Aventis) were
used. Three HPLC analyses were repeated on the same
sample and data were calculated as mean values of three
replicated analyses.
The T-A2 concentration in the sample was calculated
as follows:
T-A2 concentration (mg/L) =
C(std)× A
A(std)
× 2
where:
C (std) = concentration (mg/L) of the standard
A = area sum of the peaks T-A2-1,T - A 2-2 ,T - A 2-3,T -
A2-4, T-A2-5 in the sample
A (std) = area sum of the peaks T-A2-1, T-A2-2 , T-A2-
3, T-A2-4, T-A2-5 in the standard
2 = dilution factor
The relative content (%) of each factor of the complex
was calculated as follows:
T-A2-n(%)=
An × 100
A
where:
An = area of single peak T-A2-n in the sample where n
=1 ,2 ,3 ,4 ,5
A = area sum of the peaks T-A2-1,T - A 2-2 ,T - A 2-3,T -
A2-4, T-A2-5 in the sample
To estimate growth, mycelium was collected by centri-
fugation (3, 250 xgfor 20 min) and washed with 2 mL
isotonic saline. Dry weight was measured after 24-hour
incubation in a 50°C oven. Alternatively, 10 mL of cul-
ture were collected and centrifuged to determine PMV.
Glucose was analyzed using the Trinder assay (Sigma
Diagnostics, St. Louis, MO, USA).
Additional material
Additional file 1: Effect of different conditions of DO and pH on
growth and T-A2 production. Figure S1 shows that T-A2 titer
decreased when 300-ml Erlenmeyer flasks were filled with increasing
working volumes of the production medium TM1. Figure S2 and S3
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fermentations under different conditions of pH and DO controls. Figure
S1 - Effect of fermentation working volume on growth and T-A2
production at flask scale. Growth followed as PMV (●, solid line) and T-
A2 production (empty bars) by A. teichomyceticus ATCC 31121 were
measured in 300-ml Erlenmeyer flasks filled with increasing working
volumes of production medium. T-A2 production in standard protocols
(300-ml Erlenmeyer flasks filled with 50 ml medium) was set as 100%.
Figure S2 - Growth and teicoplanin production in 3-L batch
fermentations of A. teichomyceticus ATCC 31121. In this run, the pH
value and the pO2 were naturally self-regulated. In (A), time courses pH
(●, solid line), pO2 (□, dashed line), glucose (▲, solid line), and growth
curve measured as PMV (■, solid line). In (B), production of T-A2
measured by HPLC analysis as mg/L (filled bars). Figure S3 - Growth
and teicoplanin production in DO- and pH-controlled 3-L batch
fermentations of A. teichomyceticus ATCC 31121. In this run, the pH
value controlled by adding acid after 48 hours from inoculation and pO2
was controlled over the 20% of saturation by adjusting agitation speed.
In (A), time course of pH (●, solid line), pO2 (□, dashed line), glucose (▲,
solid line), and growth curve measured as PMV (■, solid line). In (B),
production of T-A2 measured by HPLC analysis as mg/L (filled bars).
Additional file 2: HPLC profiles of samples from A. teichomyceticus
fermentations in TM1 to which crude oils were added. Figures S4 A,
B and C show representative HPLC profiles of samples from A.
teichomyceticus fermentations in TM1 to which crude oils were added.
Figure S5 shows a comparison of HPLC profiles in the case of addition
of corn oil and L-valine. Figure S6 shows a comparison of HPLC profiles
in the case of addition of olive oil and L-valine. Figure S4 - HPLC
profiles of teicoplanin production in TM1 to which crude oils were
added. Samples from A. teichomyceticus ATCC 31121 fermentation in
TM1 to which 2.5 g/L corn oil (A), olive oil (B) and sesame oil (C) were
added and collected after 144 hours after inoculation. Figure S5 -
Comparison of HPLC profiles of teicoplanin production in TM1 to
which corn oil and L-valine were added. Samples from A.
teichomyceticus ATCC 31121 fermentation in TM1 without any addition
(solid line), 2.5 g/L corn oil added (dotted line), and 2.5 g/L corn oil and
1 g/L L-valine added (solid line). Figure S6 - Comparison of HPLC
profiles of teicoplanin production in TM1 to which olive oil and L-
valine were added. Samples from A. teichomyceticus ATCC 31121
fermentation in TM1 without any addition (solid line), 2.5 g/L olive oil
added (dotted line), and 2.5 g/L olive oil and 1 g/L L-valine added
(dashed line).
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